Presentation is loading. Please wait.

Presentation is loading. Please wait.

Biology of Blood and Marrow Transplantation

Published byCaren Price Modified over 5 years ago

Similar presentations

Presentation on theme: "Biology of Blood and Marrow Transplantation"— Presentation transcript:

1 Biology of Blood and Marrow Transplantation
Improved Event-Free Survival and Higher Incidence of Early Fever Associated with Mismatches at HLA-DRB1 after Nonmyeloablative HLA-Haploidentical Transplantation  Shannon R. McCurdy, Stephen T. Muth, Hua-Ling Tsai, Heather J. Symons, Ravi Varadhan, Richard J. Jones, Maria P. Bettinoti, Ephraim J. Fuchs  Biology of Blood and Marrow Transplantation  Volume 23, Issue 3, (March 2017) DOI: /j.bbmt Copyright © Terms and Conditions

2 Figure 1 Propensity Weighted Kaplan-Meier Overall Survival and Event-Free Survival with HLA-DRB1 Mismatch after Nonmyeloablative HLA-Haploidentical Bone Marrow Transplant. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © Terms and Conditions

Download ppt "Biology of Blood and Marrow Transplantation"

Similar presentations

Extramedullary Relapse of Acute Leukemia after Haploidentical Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, Treatment, and Clinical.

Extramedullary Relapse of Acute Leukemia after Haploidentical Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, Treatment, and Clinical.
High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Primary Central Nervous System Lymphoma (PCNSL) in First Complete Remission (CR1) 

High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Primary Central Nervous System Lymphoma (PCNSL) in First Complete Remission (CR1) 
The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk.

The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk.
The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma  Mehdi Hamadani, Erinn Hade, Don M. Benson,

The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma  Mehdi Hamadani, Erinn Hade, Don M. Benson,
Clofarabine and High-Dose Melphalan as Reduced Intensity Conditioning in Adults with High-Risk Leukemia/MDS Undergoing Allogeneic Hematopoietic Cell Transplantation 

Clofarabine and High-Dose Melphalan as Reduced Intensity Conditioning in Adults with High-Risk Leukemia/MDS Undergoing Allogeneic Hematopoietic Cell Transplantation 
Peter Hurley, Suma Konety, Qing Cao, Daniel Weisdorf, Anne Blaes 

Peter Hurley, Suma Konety, Qing Cao, Daniel Weisdorf, Anne Blaes 
Influence of Stem Cell Source on Outcomes of Allogeneic Reduced-Intensity Conditioning Therapy Transplants Using Haploidentical Related Donors  Kenneth.

Influence of Stem Cell Source on Outcomes of Allogeneic Reduced-Intensity Conditioning Therapy Transplants Using Haploidentical Related Donors  Kenneth.
Infusion of Ex Vivo Expanded Cord Blood Progenitor Cells Is Associated with Reduced Hospital Days and Utilization of Opiate Infusion and Total Parenteral.

Infusion of Ex Vivo Expanded Cord Blood Progenitor Cells Is Associated with Reduced Hospital Days and Utilization of Opiate Infusion and Total Parenteral.
The Prognostic Value of YKL-40 Concentrations in Nonmyeloablative Conditioning Allogeneic Hematopoietic Cell Transplantation  Anne Mette Mørup, Brian.

The Prognostic Value of YKL-40 Concentrations in Nonmyeloablative Conditioning Allogeneic Hematopoietic Cell Transplantation  Anne Mette Mørup, Brian.
Proteomic Biomarkers Are Predictive of Non-Relapse Mortality in Patients Treated with Post-Transplantation Cyclophosphamide Following HLA-Haploidentical.

Proteomic Biomarkers Are Predictive of Non-Relapse Mortality in Patients Treated with Post-Transplantation Cyclophosphamide Following HLA-Haploidentical.
Biology of Blood and Marrow Transplantation

Biology of Blood and Marrow Transplantation
Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years  Cynthia Huisman,

Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years  Cynthia Huisman,
Low Incidence of Chronic GVHD after HLA-Haploidentical Peripheral Blood Stem Cell Transplantation with Post Transplantation Cyclophosphamide in Older.

Low Incidence of Chronic GVHD after HLA-Haploidentical Peripheral Blood Stem Cell Transplantation with Post Transplantation Cyclophosphamide in Older.
Comparison of Outcomes after HLA-Matched Sibling and Unrelated Donor Transplantation for Children with High-Risk Acute Lymphoblastic Leukemia  Mei-Jie.

Comparison of Outcomes after HLA-Matched Sibling and Unrelated Donor Transplantation for Children with High-Risk Acute Lymphoblastic Leukemia  Mei-Jie.
Albuminuria in Hematopoietic Cell Transplantation Patients: Prevalence, Clinical Associations, and Impact on Survival  Sangeeta R. Hingorani, Kristy Seidel,

Albuminuria in Hematopoietic Cell Transplantation Patients: Prevalence, Clinical Associations, and Impact on Survival  Sangeeta R. Hingorani, Kristy Seidel,
Sabina Kersting, Leo F. Verdonck 

Sabina Kersting, Leo F. Verdonck 
HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide 

HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide 
Nonmyeloablative Haploidentical Bone Marrow Transplantation with Post- Transplantation Cyclophosphamide for Pediatric and Young Adult Patients with High-

Nonmyeloablative Haploidentical Bone Marrow Transplantation with Post- Transplantation Cyclophosphamide for Pediatric and Young Adult Patients with High-
Study Design of an Expanded Access Protocol of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Patients 60-75 Years of Age with Secondary Acute.

Study Design of an Expanded Access Protocol of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Patients Years of Age with Secondary Acute.
CD34-Selected, T Cell Depleted Haploidentical Donor Peripheral Blood Stem Cell (PBSC) Transplantation in Children with Malignant (MD) and Non-Malignant.

CD34-Selected, T Cell Depleted Haploidentical Donor Peripheral Blood Stem Cell (PBSC) Transplantation in Children with Malignant (MD) and Non-Malignant.

Similar presentations

Ads by Google